Radiopharm Theranostics LimitedASX: RAD

RAD Reports Positive Preclinical Lu177-B7H3-mAb Data

· Issued by Radiopharm Theranostics Limited

Filed with ASX · · 3 pages · English

Summary by 6ix AI

The findings confirm the antibody's potential to limit off-target exposure and mitigate toxicities associated with traditional monoclonal antibody therapies. This biodistribution study completes the preclinical package necessary for the upcoming IND application.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Radiopharm Theranostics Limited on 6ix

Story so far

Earlier from Radiopharm Theranostics

Later from Radiopharm Theranostics

All Radiopharm Theranostics news releases